Literature DB >> 18954713

Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.

Mukund Seshadri1, David A Bellnier, Richard T Cheney.   

Abstract

PURPOSE: To investigate the early effects of a vascular disrupting agent (VDA) in ectopic and orthotopic tumors by using macromolecular contrast media (MMCM)-enhanced magnetic resonance imaging (MMCM-MRI). METHODS AND MATERIALS: The MMCM-MRI of ectopic and orthotopic MCA205 murine fibrosarcomas was performed using the intravascular contrast agent albumin-(gadopentetate dimeglumine)(35). Change in longitudinal relaxation rate (DeltaR1) was measured 24 hours after treatment with 5,6-dimethylxanthenone-4-acetic acid (DMXAA; 30 mg/kg) and used to compute tumor vascular volume and permeability. Correlative histologic and immunohistochemical evaluation was carried out, along with measurement of tumor necrosis factor alpha and vascular endothelial growth factor levels in whole tumor extracts using the enzyme-linked immunosorbent assay.
RESULTS: Orthotopic tumors showed higher vascular volume (p < 0.05) than ectopic tumors before treatment. Twenty-four hours after DMXAA treatment, a significant (p < 0.0001), but differential, decrease in DeltaR1 (70% in ectopic and 50% in orthotopic tumors) was observed compared with baseline estimates. Consistent with this observation, greater levels of tumor necrosis factor alpha, an important mediator of the antivascular activity of DMXAA, were measured in ectopic tumors 3 hours posttreatment compared with orthotopic tumors (p < 0.05). Immunohistochemical (CD31) and histologic (hematoxylin and eosin) sections of ectopic and orthotopic tumors showed highly tumor-selective vascular damage after treatment with the presence of viable surrounding normal tissue.
CONCLUSIONS: The MMCM-MRI provided early quantitative estimates of change in tumor perfusion after VDA treatment that showed good correlation with cytokine induction. Differences in the response of ectopic and orthotopic tumors highlight the influence of the host microenvironment in modulating the activity of VDAs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18954713      PMCID: PMC2582978          DOI: 10.1016/j.ijrobp.2008.07.043

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  33 in total

Review 1.  Assessing tumor angiogenesis using macromolecular MR imaging contrast media.

Authors:  R Brasch; C Pham; D Shames; T Roberts; K van Dijke; N van Bruggen; J Mann; S Ostrowitzki; O Melnyk
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

2.  Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization.

Authors:  M D Ogan; U Schmiedl; M E Moseley; W Grodd; H Paajanen; R C Brasch
Journal:  Invest Radiol       Date:  1987-08       Impact factor: 6.016

3.  Toxic effect of tumor necrosis factor on tumor vasculature in mice.

Authors:  N Watanabe; Y Niitsu; H Umeno; H Kuriyama; H Neda; N Yamauchi; M Maeda; I Urushizaki
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

Review 4.  Role of the tumor microenvironment in mediating response to anti-angiogenic therapy.

Authors:  Y D Jung; S A Ahmad; Y Akagi; Y Takahashi; W Liu; N Reinmuth; R M Shaheen; F Fan; L M Ellis
Journal:  Cancer Metastasis Rev       Date:  2000       Impact factor: 9.264

5.  MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.

Authors:  Anda Preda; Viktor Novikov; Martina Möglich; Karl Turetschek; David M Shames; Robert C Brasch; Friedrich M Cavagna; Timothy P L Roberts
Journal:  J Magn Reson Imaging       Date:  2004-11       Impact factor: 4.813

Review 6.  MRI for assessing antivascular cancer treatments.

Authors:  A R Padhani
Journal:  Br J Radiol       Date:  2003       Impact factor: 3.039

7.  Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.

Authors:  Karl Turetschek; Anda Preda; Viktor Novikov; Robert C Brasch; Hanns J Weinmann; Patrick Wunderbaldinger; Timothy P L Roberts
Journal:  J Magn Reson Imaging       Date:  2004-07       Impact factor: 4.813

Review 8.  MRI of tumor angiogenesis.

Authors:  Tristan Barrett; Martin Brechbiel; Marcelino Bernardo; Peter L Choyke
Journal:  J Magn Reson Imaging       Date:  2007-08       Impact factor: 4.813

Review 9.  Specialization of tumour vasculature.

Authors:  Erkki Ruoslahti
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

10.  Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.

Authors:  Susan M Galbraith; Ross J Maxwell; Martin A Lodge; Gillian M Tozer; John Wilson; N Jane Taylor; J James Stirling; Luiza Sena; Anwar R Padhani; Gordon J S Rustin
Journal:  J Clin Oncol       Date:  2003-06-13       Impact factor: 44.544

View more
  13 in total

1.  Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer.

Authors:  Huaijun Wang; Guy Marchal; Yicheng Ni
Journal:  World J Radiol       Date:  2011-01-28

2.  Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis.

Authors:  Ravikumar Aalinkeel; Bindukumar Nair; Chih-Kuang Chen; Supriya D Mahajan; Jessica L Reynolds; Hanguang Zhang; Haotian Sun; Donald E Sykes; Kailash C Chadha; Steven G Turowski; Katelyn D Bothwell; Mukund Seshadri; Chong Cheng; Stanley A Schwartz
Journal:  Immunology       Date:  2016-08       Impact factor: 7.397

3.  Arsenic Trioxide as a Vascular Disrupting Agent: Synergistic Effect with Irinotecan on Tumor Growth Delay in a CT26 Allograft Model.

Authors:  Jong Cheol Lee; Ho Yong Lee; Chang Hoon Moon; Seung Ju Lee; Won Hyeok Lee; Hee Jeong Cha; Sungchan Park; Young Han Lee; Hyun Jin Park; Ho-Taek Song; Young Joo Min
Journal:  Transl Oncol       Date:  2013-02-01       Impact factor: 4.243

4.  Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.

Authors:  Leigh Ellis; Preeti Shah; Hans Hammers; Kristin Lehet; Paula Sotomayor; Gissou Azabdaftari; Mukund Seshadri; Roberto Pili
Journal:  Mol Cancer Ther       Date:  2011-11-14       Impact factor: 6.261

5.  Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging.

Authors:  Mukund Seshadri; Nuno T Sacadura; Tonya Coulthard
Journal:  Angiogenesis       Date:  2011-09-07       Impact factor: 9.596

6.  18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.

Authors:  Christoph Oehler; Joseph A O'Donoghue; James Russell; Pat Zanzonico; Sylvie Lorenzen; C Clifton Ling; Sean Carlin
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

7.  Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic Acid in an orthotopic model of human head and neck cancer.

Authors:  Mukund Seshadri; Karoly Toth
Journal:  Transl Oncol       Date:  2009-08-18       Impact factor: 4.243

8.  MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.

Authors:  Mukund Seshadri; Michael J Ciesielski
Journal:  J Cereb Blood Flow Metab       Date:  2009-05-20       Impact factor: 6.200

9.  The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.

Authors:  Dušan Milanović; Friederike Braun; Wolfgang Weber; Anca Ligia Grosu; Martin Behe; Gabriele Niedermann
Journal:  BMC Cancer       Date:  2012-06-13       Impact factor: 4.430

10.  KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.

Authors:  Chang Hoon Moon; Seung Ju Lee; Ho Yong Lee; Jong Cheol Lee; Heejeong Cha; Wha Ja Cho; Jeong Woo Park; Hyun Jin Park; Jin Seo; Young Han Lee; Ho-Taek Song; Young Joo Min
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.